| Literature DB >> 26732717 |
Abstract
Although malignant lymphoma is split in over 60 distinct entities, four of them, diffuse large B cell lymphoma, follicular-, Hodgkin's- and mantle cell lymphoma constitute more than half of all new cases. A recent major revision of the Ann Arbor staging system restricts the suffix “A” and “B” just to Hodgkin's lymphoma. Bone marrow exams are abandonned in Hodgkin's and restricted in DLBCL. PET exams at different time points are crucial. PET guided therapy will lead to a reduction of the use of chemo- and radiation therapy. Many new targeted drugs have been introduced. Their therapeutic index is impressive as is their price tag. The radiation and chemotherapy free treatment of malignant lymphoma is within reach.Entities:
Keywords: Hodgkin; Ibrutinib; Interim-PET; Malignes Lymphom; ibrutnib; interim PET; lymphome de Hodgkin; lymphome malin; malignant lymphoma; revidiertes Ann-Arbor-Stadium; revised Ann Arbor classification; stratification de Ann Arbor; tomographie par émission de positons
Mesh:
Substances:
Year: 2016 PMID: 26732717 DOI: 10.1024/1661-8157/a002237
Source DB: PubMed Journal: Praxis (Bern 1994) ISSN: 1661-8157